Tandem Diabetes Care, Inc. (TNDM)

$53.89

+0.33 (+0.62%)
Rating:
Recommendation:
Neutral
Symbol TNDM
Price $53.89
Beta 0.781
Volume Avg. 0.99M
Market Cap 3.461B
Shares () -
52 Week Range 52.08-155.86
1y Target Est -
DCF Unlevered TNDM DCF ->
DCF Levered TNDM LDCF ->
ROE -3.08% Neutral
ROA -1.27% Neutral
Operating Margin -
Debt / Equity 130.56% Buy
P/E 673.63 Strong Buy
P/B 7.68 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TNDM news


Mr. John Sheridan
Healthcare
Medical Devices
NASDAQ Global Market

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.